TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15817423

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) interruptions for at least two weeks
Number of subjects: 399

Group type: COMPARATOR
Intervention: Continued ART
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Treatment interruptions (TI)
Number of subjects: 399
Study: 14599005

Group type: EXPERIMENTAL
Intervention: Mixed-effects model, region-of-interest analysis of fMRI study
Number of subjects: 0
Study: 10917355

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery with a linear accelerator fitted with a multileaf collimator
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Staged therapy treating the entire volume to 10 Gy twice for AVMs with a volume of more than 25 cc
Number of subjects: 36
Study: 7862980

Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced CT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous urography (IVU)
Number of subjects: 20
Study: 1696438

Group type: EXPERIMENTAL
Intervention: Astemizole (20 mg BID for three days)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms 20 minutes before the challenge)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo of astemizole (twice a day for three days)
Number of subjects: 7
Study: 7262510

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31841482

Group type: EXPERIMENTAL
Intervention: Pathogenetic treatment of the digestive tract
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (conventional 'clean' territories)
Number of subjects: 90
Study: 28211560

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control (lenalidomide and dexamethasone)
Number of subjects: 396
Study: 26033830

Group type: EXPERIMENTAL
Intervention: Erlotinib and celecoxib
Number of subjects: 107

Group type: COMPARATOR
Intervention: Erlotinib and placebo
Number of subjects: 107
Study: 23981904

Group type: EXPERIMENTAL
Intervention: 3 g CaHMB consumed twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20957701

Group type: EXPERIMENTAL
Intervention: Weight suppression (WS)
Number of subjects: 0
Study: 19533025

Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) and conformal irradiation (dose levels: 66, 72, 78, 84 Gy)
Number of subjects: 0
Study: 17276051

Group type: EXPERIMENTAL
Intervention: 100 mcg levosalbutamol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mcg salbutamol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15504763

Group type: EXPERIMENTAL
Intervention: Early pulmonary rehabilitation programme
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study: 11949721

Group type: EXPERIMENTAL
Intervention: Multiple correspondence analysis and cluster analysis
Number of subjects: 5103

Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire
Number of subjects: 5103

Group type: EXPERIMENTAL
Intervention: Statistical approach using graphical displays
Number of subjects: 5103

Group type: EXPERIMENTAL
Intervention: Ascending hierarchical classification
Number of subjects: 5103
Study: 9272426

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate combined with 75 micrograms levonorgestrel
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 10 mg medroxyprogesterone acetate (MPA)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 75 micrograms levonorgestrel
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 1 mg cyproterone acetate
Number of subjects: 139
Study: 7519112

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 2900084

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 micrograms.kg‐1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sufentanil 1.0 micrograms.kg‐1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sufentanil 1.5 micrograms.kg‐1
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30975196

Group type: EXPERIMENTAL
Intervention: Curcumin 500-mg capsule three times daily
Number of subjects: 139

Group type: COMPARATOR
Intervention: Diclofenac 50-mg tablet two times daily
Number of subjects: 139
Study: 28930769

Group type: EXPERIMENTAL
Intervention: Alcohol (target blood alcohol concentration = 0.080%)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo alcohol (target blood alcohol concentration = 0.000%)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 282
Study: 25441978

Group type: EXPERIMENTAL
Intervention: Osseous Resective Surgery (ORS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fibre Retention Osseous Resective Surgery (FibReORS)
Number of subjects: 26
Study: 23682927

Group type: EXPERIMENTAL
Intervention: Feedback from the expert group
Number of subjects: 286

Group type: COMPARATOR
Intervention: Feedback from the community group
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Rating panel composed of at least 15 raters
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Time 2 ratings
Number of subjects: 286
Study: 20936308

Group type: EXPERIMENTAL
Intervention: Mild degeneration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate degeneration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Severe degeneration
Number of subjects: 30
Study: 18004709

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study: 16172147

Group type: EXPERIMENTAL
Intervention: Two etonogestrel rods (204 mg etonogestrel) and 400 mg testosterone decanoate every 4 weeks (group I, n = 42)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Two etonogestrel rods (204 mg etonogestrel) and 400 mg testosterone decanoate every 6 weeks (group II, n = 51)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Two etonogestrel rods (204 mg etonogestrel) and 600 mg testosterone decanoate every 6 weeks (group III, n = 37)
Number of subjects: 130
Study: 14669843

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate (E2V)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate (E2V) + 3 mg dienogest (DNG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 11079281

Group type: EXPERIMENTAL
Intervention: 20 minutes of education on the use of a metered-dose inhaler (MDI)-spacer device
Number of subjects: 83
Study: 8646142

Group type: EXPERIMENTAL
Intervention: Pituitary suppression with a luteinising hormone releasing hormone analogue followed by low dose ovulation induction and luteal phase progesterone
Number of subjects: 106
Study: 1330192

Group type: EXPERIMENTAL
Intervention: Conventional ultrasound (US)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Duplex sonography (DS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 22
Study: 3872000

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 20
Study: 30987963

Group type: EXPERIMENTAL
Intervention: MitraClip transcatheter mitral valve repair
Number of subjects: 330

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 330
Study: 30561402

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based preoperative chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative radiation alone
Number of subjects: 0
Study: 27579261

Group type: EXPERIMENTAL
Intervention: Albanian's Health Promoting Schools Model (Albanian's HPSM) intervention for 6 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Albanian's Health Promoting Schools Model (Albanian's HPSM) intervention
Number of subjects: 120
Study: 24754328

Group type: EXPERIMENTAL
Intervention: Oral prenatal probiotic (Florajen3) taken once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no probiotic)
Number of subjects: 20
Study: 22548396

Group type: EXPERIMENTAL
Intervention: Excimer-dye laser (EDL) (630 nm)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metal-halide lamp (MHL) (600 to 740 nm)
Number of subjects: 25
Study: 21173319

Group type: EXPERIMENTAL
Intervention: Indoor tanning use
Number of subjects: 2869

Group type: COMPARATOR
Intervention: Demographic and lifestyle factors
Number of subjects: 2869

Group type: COMPARATOR
Intervention: Skin cancer knowledge and attitudes
Number of subjects: 2869

Group type: COMPARATOR
Intervention: Skin cancer knowledge and perceived risk
Number of subjects: 2869
Study: 16516188

Group type: EXPERIMENTAL
Intervention: Cooperative task
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Competitive task
Number of subjects: 2

Group type: COMPARATOR
Intervention: Isolation (not explicitly mentioned as a control)
Number of subjects: 2
Study: 16376767

Group type: EXPERIMENTAL
Intervention: Presence of spontaneous echocontrast (SEC) in the left atrial appendage (LAA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: LAA wall velocity
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: LAA flow velocity
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: LAA tissue intensity
Number of subjects: 47
Study: 12086760

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg three times daily
Number of subjects: 682

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 682
Study: 9862412

Group type: EXPERIMENTAL
Intervention: Oxygen administration 5 min prior to word presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxygen administration immediately before word presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxygen administration immediately following word presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen administration 10 min prior to word presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen administration 5 min following word presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen administration 10 min following word presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxygen administration for 2 min during the experiment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen administration
Number of subjects: 0
Study: 7638804

Group type: EXPERIMENTAL
Intervention: Nebulised morphine (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebulised morphine (25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (1 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (2.5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2692816

Group type: EXPERIMENTAL
Intervention: Theophylline (5.5 mg of the ethylendiamine salt.kg‐1 intravenously)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31508863

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg/kg) with paracetamol (1 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tramadol (1 mg/kg)
Number of subjects: 60
Study: 31703247

Group type: EXPERIMENTAL
Intervention: Fluid replacement (EUHFL and HYPOFL; 10 min ad libitum consumption)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No fluid replacement (EUHNF and HYPONF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluid replacement (HYPOFL)
Number of subjects: 12
Study: 27020912

Group type: EXPERIMENTAL
Intervention: CPP‐ACP sugar‐free chewing gum
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular sugar‐free chewing gum without CPP‐ACP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saliva-no chewing gum
Number of subjects: 10
Study: 25209313

Group type: EXPERIMENTAL
Intervention: Patient self-testing (PST) every 4 weeks
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Patient self-testing (PST) weekly
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Patient self-testing (PST) twice weekly
Number of subjects: 787

Group type: COMPARATOR
Intervention: High quality anticoagulation management (HQACM) with venous INR testing every 4 weeks
Number of subjects: 787
Study: 23638622

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (60 mg/day) for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 64
Study: 21205325

Group type: EXPERIMENTAL
Intervention: Polypill (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril, 12.5 mg hydrochlorothiazide)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard Practice (individual drugs)
Number of subjects: 216
Study: 19419544

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional antiepileptic drugs
Number of subjects: 70
Study: 16968583

Group type: EXPERIMENTAL
Intervention: Travoprost (TRAV; travoprost 0.004%)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fixed-combination of dorzolamide/timolol (DTFC; dorzolamide 2.0%/timolol maleate 0.5%)
Number of subjects: 56
Study: 15367414

Group type: EXPERIMENTAL
Intervention: Myocet (M; 75 mg/m(2)) + cyclophosphamide (C; 600 mg/m(2))
Number of subjects: 160

Group type: COMPARATOR
Intervention: Epirubicin (E; 75 mg/m(2)) + cyclophosphamide (C; 600 mg/m(2))
Number of subjects: 160
Study: 11967795

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (2-32 mg) over a median period of 84 days (range: 1-418 days)
Number of subjects: 1893

Group type: COMPARATOR
Intervention: Placebo over a median period of 85 days (range: 1-398 days)
Number of subjects: 1893
Study: 9174296

Group type: EXPERIMENTAL
Intervention: alfentanil 40 microg/kg followed by propofol 2 mg/kg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: alfentanil 40 microg/kg followed by etomidate 0.3 mg/kg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: alfentanil 40 microg/kg followed by thiopental 4 mg/kg
Number of subjects: 140

Group type: COMPARATOR
Intervention: d-tubocurarine 3 mg followed by thiopental 4 mg/kg and succinylcholine 1 mg/kg
Number of subjects: 140
Study: 8465885

Group type: EXPERIMENTAL
Intervention: Buspirone added to fluvoxamine therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3763655

Group type: EXPERIMENTAL
Intervention: 20 mg penbutolol and 3 mg piretanide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29780062

Group type: EXPERIMENTAL
Intervention: Chlorella (6 g/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (7.2 g/day lactose)
Number of subjects: 27
Study: 26807672

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg intravenously over 40 min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25264974

Group type: EXPERIMENTAL
Intervention: WEBCARE (12-week fixed, six-lesson behavioral treatment based on cognitive behavioral therapy)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 289
Study: 21969363

Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 242

Group type: COMPARATOR
Intervention: Community practice
Number of subjects: 242
Study: 19898831

Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg subcutaneous)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18515527

Group type: EXPERIMENTAL
Intervention: SAFE intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16037172

Group type: EXPERIMENTAL
Intervention: Espocan (ES) 18-gauge modified epidural needle with 27-gauge Pencan atraumatic spinal needle
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tuohy 18-gauge conventional needle with 27-gauge Gertie Marx atraumatic spinal needle
Number of subjects: 100
Study: 12425803

Group type: EXPERIMENTAL
Intervention: Pantoprazole triple regimen (pantoprazole 40 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 1-week)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 1-week)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Pantoprazole triple regimen (pantoprazole 40 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 2-weeks)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, metronidazole 400 mg, bid, for 2-weeks)
Number of subjects: 147
Study: 10523330

Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% fat, 54% carbohydrate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-fat diet (45% fat, predominantly saturated fat, 36% carbohydrate)
Number of subjects: 14
Study: 7627480

Group type: EXPERIMENTAL
Intervention: Light reflective rheography (LRR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ascending venography
Number of subjects: 0
Study: 2034245

Group type: EXPERIMENTAL
Intervention: 0.125 mg of triazolam
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 7047341

Group type: EXPERIMENTAL
Intervention: Oxmetidine (400 mg b.i.d.)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cimetidine (1 g/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oxmetidine
Number of subjects: 39
Study: 31319053

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no sedation mentioned)
Number of subjects: 120
Study: 28772131

Group type: EXPERIMENTAL
Intervention: Walk-on-the-line group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 25970543

Group type: EXPERIMENTAL
Intervention: Tumour ESR1 gene expression
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Absence of necrosis
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: mRNA‐based Immune Score (mIS) in stage III right‐sided colon cancer
Number of subjects: 344
Study: 23361158

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (50,000 IU weekly for 12 weeks followed by 50,000 IU every other week for 40 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 1 year)
Number of subjects: 46
Study: 21718620

Group type: EXPERIMENTAL
Intervention: Valplast dentures (group A)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional removable partial dentures (group B)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 76
Study: 19390704

Group type: EXPERIMENTAL
Intervention: Amlodipine + Enalapril (A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amlodipine (B)
Number of subjects: 72
Study: 17047649

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (30 mg/m²), epirubicin (50 mg/m²), and paclitaxel (120 mg/m²) with granulocyte-colony stimulating factor support (PET)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tri-weekly epirubicin (90 mg/m²) and paclitaxel (175 mg/m²) (ET)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin, epirubicin, and paclitaxel (PET)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tri-weekly epirubicin and paclitaxel (ET)
Number of subjects: 200
Study: 14723987

Group type: EXPERIMENTAL
Intervention: Artesunate (3 days)
Number of subjects: 5948

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 5948

Group type: EXPERIMENTAL
Intervention: Artesunate (1 day)
Number of subjects: 5948
Study: 11760527

Group type: EXPERIMENTAL
Intervention: Injection speed of 10 s/cc
Number of subjects: 50

Group type: COMPARATOR
Intervention: Injection speed of 30 s/cc
Number of subjects: 50
Study: 9292380

Group type: EXPERIMENTAL
Intervention: Home-based multisystemic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8161675

Group type: EXPERIMENTAL
Intervention: Single-dose sodium phosphate solution regimen (Fleet Phospho-Soda)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional polyethylene glycol (PEG)-electrolyte lavage
Number of subjects: 52

Group type: COMPARATOR
Intervention: PEG lavage
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sodium phosphate regimen
Number of subjects: 52
Study: 3745848

Group type: EXPERIMENTAL
Intervention: Regular coffee (100 ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (100 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sugared water (100 ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Regular coffee (50 ml)
Number of subjects: 10
Study: 29807719

Group type: EXPERIMENTAL
Intervention: Minimalist Footwear (MFW)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional Running Shoes (CRS)
Number of subjects: 32
Study: 27181509

Group type: EXPERIMENTAL
Intervention: tDCS active (bilateral, 20-min session at 2mA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: tDCS sham (bilateral, 20-min session)
Number of subjects: 10
Study: 24398734

Group type: EXPERIMENTAL
Intervention: 1-h educational intervention for anesthesia faculty
Number of subjects: 71
Study: 23656644

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 20609130

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) administered intradermally and subcutaneously, 5 units/site, total dose 40-200 units.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (control group for 8 patients in randomized trial).
Number of subjects: 14
Study: 18990047

Group type: EXPERIMENTAL
Intervention: Active plant (vortex-rotated tap water)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control plant (tap water)
Number of subjects: 50
Study: 15855884

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (estrogen and gestagen)
Number of subjects: 39
Study: 14621090

Group type: EXPERIMENTAL
Intervention: Comprehensive self-management intervention (skill-oriented patient education programme and near-home fitness programme, on top of usual care)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Comprehensive self-management intervention
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (usual care by the treating chest physician)
Number of subjects: 248
Study: 10806378

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone antibiotics (FQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 0